Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 360º synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increase in diagnosis rate of hematological cancers
3.2.1.2 Improved healthcare infrastructure
3.2.1.3 Advancement in diagnostic technologies
3.2.1.4 Increasing incidence of hematologic malignancies
3.2.2 Industry pitfalls & challenges
3.2.2.1 Competition from alternative diagnostic methods
3.2.2.2 High maintenance and operational cost
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Future market trends
3.6 Porter’s analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategic dashboard
Chapter 5 Market Estimates and Forecast, By Product & Service, 2021 - 2032 ($ Million)
5.1 Key trends
5.2 Instrument
5.2.1 Next-generation sequencing (NGS)
5.2.2 Polymerase chain reaction (PCR)
5.2.3 Flow cytometry
5.2.4 Cytogenetics
5.2.5 Immunohistochemistry (IHC)
5.2.6 Other technologies
5.3 Kits & reagents
5.4 Software & service
Chapter 6 Market Estimates and Forecast, By Cancer Type, 2021 - 2032 ($ Million)
6.1 Key trends
6.2 Leukemia
6.2.1 Acute lymphoblastic leukemia (ALL)
6.2.2 Acute myeloid leukemia (AML)
6.2.3 Chronic lymphocytic leukemia (CLL)
6.2.4 Chronic myeloid leukemia (CML)
6.3 Lymphoma
6.3.1 Hodgkin lymphoma
6.3.2 Non-Hodgkin lymphoma (NHL)
6.4 Other cancer types
Chapter 7 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Million)
7.1 Key trends
7.2 Hospitals & clinics
7.3 Diagnostic laboratories
7.4 Other end-users
Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Million)
8.1 Key trends
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Spain
8.3.5 Italy
8.3.6 Netherlands
8.3.7 Rest of Europe
8.4 Asia Pacific
8.4.1 Japan
8.4.2 China
8.4.3 India
8.4.4 Australia
8.4.5 South Korea
8.4.6 Rest of Asia Pacific
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Rest of Latin America
8.6 Middle East and Africa
8.6.1 South Africa
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Rest of Middle East and Africa
Chapter 9 Company Profiles
9.1 Abbott Laboratories
9.2 ARUP Laboratories
9.3 Bio-Rad Laboratories Inc.
9.4 Danaher Corporation (Integrated DNA Technologies, Inc.)
9.5 Entrogen Inc.
9.6 F. Hoffmann-La Roche Ltd
9.7 Illumina, Inc.
9.8 Invivoscribe, Inc.
9.9 Invitae Corporation (Archerdx, Inc.)
9.10 QIAGEN N.V.
9.11 Thermo Fisher Scientific, Inc.
9.12 Vela Diagnostics
